CRCamila Renjifo-Ibañez

Camila Renjifo-Ibañez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camila Renjifo-Ibañez has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Angélica María Zuluaga-Cabrera

    Grupo de Investigación GISCA, Facultad de Medicina Veterinaria y Zootecnia, Fundación Universitaria Vision de las Américas, Medellín 050031, Colombia

    1 shared publication
  • Carlos Alberto Madrid Bracamonte

    Tech Life Saving (TLS), Tech Innovation Group Company, Medellin 050022, Colombia

    1 shared publication
  • Daniel F. Rojas-Tapias

    Colección de Microorganismos de Interés en Biofertilizantes, Laboratorio de Microbiología Agrícola, Centro de Investigación Tibaitatá, Corporación Colombiana de Investigación Agropecuaria – AGROSAVIA, Mosquera, Colombia

    1 shared publication
  • Jeisson Gómez-Robles

    Grupo de Investigación en Toxinología, Alternativas Terapéuticas y Alimentarias, Universidad de Antioquia, Medellín 050010, Colombia

    1 shared publication
  • Leidy Johana Vargas-Muñoz

    Facultad de Medicina, Universidad Cooperativa de Colombia, Calle 50 A No 41-20, Medellín, 050012, Antioquia, Colombia

    1 shared publication
  • Ligia D Torres-Higuera

    Colección de Microorganismos de Interés en Salud Animal, Laboratorio de Microbiología Pecuaria, Centro de Investigación Tibaitatá, Corporación Colombiana de Investigación Agropecuaria (AGROSAVIA), Mosquera, Colombia

    1 shared publication

Latest Publications

  • Comprehensive genotyping and taxonomic analysis uncovers extensive distribution of intermediate Leptospira species in Colombia

    by Ligia D Torres-Higuera, Daniel F. Rojas-Tapias, Sabrina Jiménez-Velásquez, Camila Renjifo-Ibáñez

    Leptospirosis, a globally prevalent zoonosis caused by pathogenic and intermediate Leptospira species, poses significant threats to public health and livestock industries. Despite its substantial impact, knowledge gaps persist regarding the prevalence and genetic diversity of Leptospira strains in many regions, including South America. This study aimed to characterize a diverse collection of Leptospira strains isolated from various sources in Colombia to enhance our understanding of the genetic diversity within this genus. Using a tiered approach combining conventional and genomic methods, we genotyped 55 isolates from various sources using 16S rRNA and rpoB gene sequencing, DNA ribotyping, and Multiple-Locus Variable-Number Tandem Repeat Analysis (MLVA). Most isolates were classified into phylogenetic groups containing pathogenic and intermediate strains of L. interrogans and L. wolffii, respectively, which was corroborated by ribotyping and MLVA. Whole-genome sequencing of selected strains revealed distinct genomic characteristics compared to related strains. Pan-genome analysis identified strain-specific genes, primarily hypothetical, while virulence factor analysis distinguished species-specific patterns. Furthermore, CRISPR-Cas system analysis uncovered genetic variations among the isolates. This study provides a framework for understanding Leptospira genetic diversity in Colombia and its potential implications on human and animal health. Our findings highlight the need for improved diagnostic methods and surveillance strategies that encompass both pathogenic and intermediate Leptospira species, which could significantly impact public health policies and veterinary practices in the region.

  • Open Access

    Standard Quality Characteristics and Efficacy of a New Third-Generation Antivenom Developed in Colombia Covering Micrurus spp. Venoms

    by Santiago Tabares Vélez, Lina María Preciado, Leidy Johana Vargas Muñoz, Carlos Alberto Madrid Bracamonte, Angelica Zuluaga, Jeisson Gómez Robles, Camila Renjifo-Ibañez, Sebastián Estrada-Gómez

    In Colombia, Micrurus snakebites are classified as severe according to the national clinical care guidelines and must be treated with specific antivenoms. Unfortunately, these types of antivenoms are scarce in certain areas of the country and are currently reported as an unavailable vital medicine. To address this issue, La Universidad de Antioquia, through its spin-off Tech Life Saving, is leading a project to develop third-generation polyvalent freeze-dried antivenom. The goal is to ensure access to this therapy, especially in rural and dispersed areas. This project aims to evaluate the physicochemical and preclinical parameters (standard quality characteristics) of a lab-scale anti-elapid antivenom batch. The antivenom is challenged against the venoms of several Micrurus species, including M. mipartitus, M. dumerilii, M. ancoralis, M. dissoleucus, M. lemniscatus, M. medemi, M. spixii, M. surinamensis, and M. isozonus, following the standard quality characteristics set by the World Health Organization (WHO). The antivenom demonstrates an appearance consistent with standards, 100% solubility within 4 min and 25 s, an extractable volume of 10.39 mL, a pH of 6.04, an albumin concentration of 0.377 mg/mL (equivalent to 1.22% of total protein), and a protein concentration of 30.97 mg/mL. Importantly, it maintains full integrity of its F(ab′)2 fragments and exhibits purity over 98.5%. Furthermore, in mice toxicity evaluations, doses up to 15 mg/mouse show no toxic effects. The antivenom also demonstrates a significant recognition pattern against Micrurus venoms rich in phospholipase A2 (PLA2) content, as observed in M. dumerilii, M. dissoleucus, and M. isozonus. The effective dose 50 (ED50) indicates that a single vial (10 mL) can neutralize 2.33 mg of M. mipartitus venom and 3.99 mg of M. dumerilii venom. This new anti-elapid third-generation polyvalent and freeze-dried antivenom meets the physicochemical parameters set by the WHO and the regulators in Colombia. It demonstrates significant efficacy in neutralizing the venom of the most epidemiologically important Micrurus species in Colombia. Additionally, it recognizes seven other species of Micrurus venom with a higher affinity for venoms exhibiting PLA2 toxins. Fulfilling these parameters represents the first step toward proposing a new pharmacological alternative for treating snakebites in Colombia, particularly in dispersed rural areas, given that this antivenom is formulated as a freeze-dried product.